Developing novel therapy to improve outcomes in MCL

开发新疗法以改善 MCL 的预后

• 批准号: 10717196
• 负责人: Lalit Sehgal
• 金额: $ 40.7万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-12 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10717196
• 关键词: Ablation; Biological; Biology; Biopsy; CDC2 gene; CDKN1C gene; Cell Cycle; Cell Cycle Arrest; Cell Death; Cell Line; Cell Survival; Chemoresistance; Clinic; Clinical; Combined Modality Therapy; Data; Development; Dose; E2F transcription factors; EZH2 gene; Feedback; Fibroblast Growth Factor Receptor 1; Fibroblast Growth Factor Receptors; Gene Expression; Genes; Genetic; Genetically Engineered Mouse; Goals; Hematopoietic Neoplasms; Homologous Gene; In Vitro; Investigation; Knowledge; Lymphoma cell; Mantle Cell Lymphoma; Mediating; Membrane; Methods; Molecular; Non-Hodgkin' s Lymphoma; Outcome; Pathway interactions; Patients; Physiological; Play; Pre-Clinical Model; Process; Prognosis; Progression-Free Survivals; Proteins; Receptor Protein-Tyrosine Kinases; Refractory; Relapse; Resistance; Role; Sampling; Schedule; Signal Pathway; Signal Transduction; TK1 gene; Therapeutic; Tissues; Toxic effect; Transactivation; Translating; Up-Regulation; angiogenesis; c-myc Genes; carcinogenesis; clinical decision-making; clinical efficacy; clinically significant; cohort; improved; improved outcome; in vivo; inhibitor; migration; mouse model; novel; novel therapeutic intervention; novel therapeutics; outcome prediction; overexpression; patient derived xenograft model; patient population; pharmacologic; pre-clinical; pre-clinical assessment; preclinical study; preclinical trial; prevent; programs; response; small molecule; synergism; targeted treatment; therapeutic target; tumor; virtual

PROJECT SUMMARY Mantle cell lymphoma (MCL) is an incurable non-Hodgkin lymphoma, and despite intensive therapeutic approaches, the median progression-free survival after first-line treatment is four years. The emergence of chemoresistance is rapid, durable responses to second and third-line therapies are rare, and relapse is virtually universal in MCL. Cell cycle dysregulation, primarily by upregulation of E2F1 target genes, is a hallmark of MCL. We identified a novel role of Fibroblast growth factor receptor-1 (FGFR1) in MCL survival and regulating cell cycle-dependent processes primarily by inhibiting E2F1 mediated transactivation. We show that FGFR1 and not other homologs are overexpressed in MCL patients, and its expression is associated with a poor prognosis. Functionally, genetic ablation of FGFR1 or pharmacological targeting with erdafitinib, a selective small molecule targeting FGFRs, induced cell cycle arrest, cell death in-vitro, reduced tumor formation, and improved overall survival in-vivo. Mechanistically, we show that FGFR1 positively regulates E2F1-mediated transactivation of its target gene through cMYC/EZH2/CDKN1C axis, contributing to cell survival. Hence, we hypothesize that the FGFR1 signaling pathway is a critical modulator of cell survival and represents a novel and attractive candidate for targeted therapy for patients with relapsed MCL. In this proposal, we will dissect the mechanisms by which FGFR1 impacts MCL survival and perform preclinical studies using erdafitinib as a therapy to prevent and treat MCL through the following specific aims: SA1: To characterize the role of FGFR1 in MCL survival in-vitro and in- vivo mouse models of MCL. In this aim, we will investigate a) FGFR1's role in regulating E2F1 mediated transactivation of target genes and survival in-vivo, b) the role of CDKN1C in regulating E2F1 dependent transactivation program, c) the role of E2F1 target gene CDK1, to positively regulates cMYC stability and constitute a feedback loop and d) identify mechanism-based combination strategies to maximize the therapeutic potential of FGFR1 inhibition. SA2:To conduct a preclinical investigation of inhibition of FGFR1 using patient- derived xenograft (PDX) murine models and a primary genetic murine model of MCL. We will conduct a preclinical trial of erdafitinib using PDX and murine models of MCL to identify a) the doses of erdafitinib that induce efficient inhibtion of FGFR1 signaling and downstream target gene expression without unacceptable toxicity and b) the best dose and schedule of erdafitinib resulting in maximum clinical efficacy alone and c) in combination with an ibrutinib. SA3: We will perform a retrospective analysis on tissue biopsies from relapsed MCL patients to a) analyze the effects of FGFR1 protein and its associated clinical outcomes and b) analyze the correlation between FGFR1 protein and, its activation, downstream effectors in patients with relapsed/refractory MCL. Impact: Our proposal will establish the role of FGFR1 in regulating E2F1 dependent transactivation program in MCL and provide a robust preclinical assessment by evaluating the toxicity, exposure, and efficacy of erdafitnib in preclinical models of MCL to translate FGFR1 inhibitor erdafitinib to treat MCL in clinics.

项目总结